Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND
- Written by PR Newswire
SHANGHAI, July 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National Medical Products Administration (NMPA). 9MW2921 is developed by Mabwell's novel antibody-drug conjugate platef...
Read more: Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND